OncoMatch/Clinical Trials/Lung Cancer — Non-Small Cell (NSCLC)
Lung Cancer — Non-Small Cell (NSCLC) Clinical Trials
OncoMatch filters Lung Cancer — Non-Small Cell (NSCLC) trials by the molecular markers that determine eligibility — EGFR, ALK, ROS1, KRAS, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Lung Cancer — Non-Small Cell (NSCLC) trials
These are the molecular markers most commonly required or evaluated in Lung Cancer — Non-Small Cell (NSCLC) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Bristol-Myers Squibb
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
How OncoMatch finds Lung Cancer — Non-Small Cell (NSCLC) trials for you
AI reads the protocol
Every Lung Cancer — Non-Small Cell (NSCLC) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Lung Cancer — Non-Small Cell (NSCLC) and mark your biomarker results — EGFR, ALK, ROS1 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.